CPHI Stock News China Pharma Holdings (CPHI) 0.32 08/02/2014

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2014 at 3:34 AM

China Pharma Holdings (CPHI) 0.32 $CPHI

Analytical Notes on Health Care Equities -- Research on TherapeuticsMD, China Pharma Holdings, Pacira Pharma, and Lannett
PR Newswire - Wed Mar 26, 10:15AM CDT
The trading session on Tuesday, March 25, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,367.88, up 0.56% and the NASDAQ Composite closed at 4,234.27, up 0.19%. The S&P 500 finished the session 0.44% higher at 1,865.62. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day 0.83% higher at 671.69, while the same has advanced 5.27% in the last three months. Investor-Edge has initiated coverage on the following equities: TherapeuticsMD Inc. (NYSE MKT: TXMD), China Pharma Holdings Inc. (NYSE MKT: CPHI), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Lannett Co. Inc. (NYSE: LCI). Free technical research on TXMD, CPHI, PCRX, and LCI can be downloaded upon signing up at:

China Pharma Holdings, Inc. Reports Full Year 2013 Financial Results
PR Newswire - Fri Mar 21, 5:00AM CDT
China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma" or the "Company"

, an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2013.

China Pharma Holdings Announces Updated Dial-in Information for Its Fiscal Year 2013 Earnings Conference Call
PR Newswire - Fri Mar 21, 12:00AM CDT
China Pharma Holdings, Inc. ("China Pharma"

(NYSE MKT: CPHI), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, announced today updated dial-in information for its fiscal year 2013 earnings conference call. Below is the updated information.

CPHI to Hold Fiscal Year 2013 Earnings Conference Call on Friday, March 21, 2014 at 8:30 a.m. ET
PR Newswire - Wed Mar 12, 7:00AM CDT
China Pharma Holdings, Inc. ("China Pharma"

(NYSE MKT: CPHI), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that it plans to hold its fiscal year 2013 earnings conference call on Friday, March 21 2014 at 8:30 a.m. ET.

4 Biotech Stocks Under $10 to Watch
at The Street - Tue Feb 18, 1:30PM CST
Keep these under-$10 biotech stocks trading on unusual volume on your radar.

China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
PR Newswire - Thu Jan 16, 7:00AM CST
China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma" or the "Company"

, a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on January 14, 2014, the NYSE MKT has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it knows of no event or series of events that could have caused such market activity.

OTC Signal Daily Stock Watch - China Pharma Holdings, Inc. (NYSE: CPHI)
WorldStockWire - Wed Sep 04, 2:15AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com

China Pharma Holdings Inc falls to net loss of USD4.5m in Q2 2013
M2 - Fri Aug 16, 9:35AM CDT
Pharmaceutical company China Pharma Holdings Inc (NYSE MKT:CPHI) on Thursday declared a net loss of USD4.5m (loss per basic and diluted common share of USD0.10) for the three months ended 30 June 2013.

China Pharma Holdings, Inc. Reports Second Quarter 2013 Financial Results
PR Newswire - Thu Aug 15, 5:00AM CDT
China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma", the "Company" or "we"

, an NYSE MKT listed corporation with its fully-integrated specialty pharmaceutical subsidiary based in China, today announced financial results for the three months ended June 30, 2013.

CPHI to Hold Second Quarter of Fiscal Year 2013 Earnings Conference Call on Thursday, August 15, 2013 at 8:30 a.m. ET
PR Newswire - Thu Aug 01, 7:00AM CDT
China Pharma Holdings, Inc. ("China Pharma"

(NYSE MKT: CPHI), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that it plans to hold its second quarter of year 2013 earnings conference call on Thursday, August 15, 2013 at 8:30 a.m. ET.

VTG, WX, CPHI, TYPE, ITA, CTGX Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed May 15, 7:07AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Vantage Drilling Co (AMEX:VTG), Wuxi Pharmatech (Cayman) Inc (NYSE:WX), China Pharma Holdings Inc (AMEX:CPHI), Monotype Imaging Holdings Inc (NASDAQ:TYPE), iShares Dow Jones US Aerospace and Defense Index Fund (NYSE:ITA), Computer Task Group Inc (NASDAQ:CTGX) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

China Pharma Holdings Inc announces lower net income of USD4.6m in 2012
M2 - Mon Mar 18, 10:25AM CDT
Pharmaceutical company China Pharma Holdings Inc (NYSE MKT:CPHI) announced on Friday its net income of USD4.6m (USD0.11 per basic and diluted share) for the year ended 31 December 2012.

CPHI to Hold Fiscal Year 2012 Earnings Conference Call on Friday, March 15, 2013 at 8:30 a.m. ET
PR Newswire - Tue Mar 05, 5:00AM CST
China Pharma Holdings, Inc. ("China Pharma"

(NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it plans to hold its fiscal year 2012 earnings conference call on Friday, March 15, 2013 at 8:30 a.m. ET.

CPHI, Removed From Naked Short Lists Today
M2 - Mon Jan 28, 8:54AM CST
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. China Pharma Holdings Inc (AMEX:CPHI). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .

CPHI, Has Remained On Naked Short Lists 13 Consecutive Days
M2 - Wed Jan 23, 8:56AM CST
BUYINS.NET, www.buyins.net , announced today that these select companies have been Has Remained On the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. China Pharma Holdings Inc (AMEX:CPHI). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .

SCM, SHCAY, CPHI, Added To Naked Short Lists Today
M2 - Fri Jan 04, 8:54AM CST
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. SWISSCOM AG ADS (NYSE:SCM), Sharp Corp (OTC:SHCAY), China Pharma Holdings Inc (AMEX:CPHI). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Survivors Secure $800M Settlement with NY Archdiocese

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Alaska's Insurance Maze: Coverage Over Cheap Policies

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...